BIGBEAR
PHARMACEUTICAL
Selpercatinib is a highly selective and potent kinase inhibitor that exerts its therapeutic effect by selectively targeting and inhibiting mutated or fusion forms of the RET gene.
AuthenticGuaranteeFast DeliveryPrivacy Selpercatinib is a highly selective RET kinase inhibitor used to treat various solid tumors, including non-small cell lung cancer and medullary thyroi···【More】
Update: 29 May,2026Source: BigbearViews: 99
Selpercatinib is a highly selective RET kinase inhibitor used for the treatment of various cancers (such as non-small cell lung cancer, medullary thyr···【More】
Update: 29 May,2026Source: BigbearViews: 90
On May 8, 2020, the U.S. Food and Drug Administration (FDA) approved Retevmo (selpercatinib), an oral RET inhibitor developed by Eli Lilly's subsi···【More】
Update: 29 May,2026Source: BigbearViews: 98
Selpercatinib is a targeted therapy for specific gene mutations (such as RET fusion-positive), primarily used to treat malignant tumors such as thyroi···【More】
Update: 27 Feb,2026Source: BigbearViews: 98
Selpercatinib is a targeted drug that targets specific gene mutations (such as RET fusions or mutations) and is primarily used to treat malignant tumo···【More】
Update: 27 Feb,2026Source: BigbearViews: 104
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
